β-肾上腺素能受体在肿瘤免疫调节中的研究进展  

Research progress on the role ofβ-adrenergic receptor in tumor immunomodulation

作　　者：秦梅 袁晓莉 米亭同 王振波[1] Qin Mei;Yuan Xiaoli;Mi Tingtong;Wang Zhenbo(Department of Oncology,Binzhou Medical University Hospital,Binzhou 256600,China)

机构地区：[1]滨州医学院附属医院肿瘤科,滨州256600

出　　处：《国际医药卫生导报》2023年第19期2720-2723,共4页International Medicine and Health Guidance News

摘　　要：免疫治疗是一种新型抗肿瘤治疗方式,但由于免疫抑制的存在,使部分免疫治疗患者出现免疫抵抗,免疫调节剂是克服和延缓免疫耐药重要途径之一。目前,改善免疫治疗的方法主要包括激活免疫共刺激信号、阻断免疫共抑制信号、调节肿瘤微环境和靶向T细胞活化等。β-肾上腺素能信号介导的应激与肿瘤免疫之间存在联系,与免疫相关的免疫细胞表面广泛表达β-肾上腺素能受体,并受其相应神经递质的调节,从而影响肿瘤的免疫反应。抑制β-肾上腺素能受体,特别是β2-肾上腺素能受体,能显著改善肿瘤免疫微环境,增强免疫检查点抑制剂、肿瘤疫苗等免疫治疗的疗效。本文综述β-肾上腺素能受体免疫调节作用的研究进展。Immunotherapy is a new anti-tumor therapy,but due to the existence of immunosuppression,some immunotherapy patients have immune resistance.Immunomodulators are one of the important ways to overcome and delay the immune resistance.At present,the methods of improving immunotherapy mainly include activating immune costimulatory signals,blocking co-immunosuppressive signals,regulating tumor microenvironment,and targeting T cell activation.More and more clinical studies have showed that there is a relationship betweenβ-adrenergic signal-mediated stress and tumor immunity.β-adrenergic receptors are widely expressed on the surface of immune cells related to immunity,and are regulated by their corresponding neurotransmitters,thus affecting the immune response of tumors.It is found that inhibitingβ-adrenergic receptor,especiallyβ2-adrenergic receptor,can significantly improve the tumor immune microenvironment and enhance the efficacy of immunotherapy such as checkpoint inhibitors and tumor vaccines.This paper reviews the research progress of immunoregulation ofβ-adrenergic receptor.

关 键 词：肿瘤 Β-肾上腺素能受体 免疫治疗 肿瘤免疫微环境 进展 

分 类 号：R730.3[医药卫生—肿瘤]